Skip to content
Disclosery

ARCH Venture Management, LLC

Follow

13F filer, CIK 1274403, CHICAGO, IL

ARCH Venture Management, LLC reported $299,110,134 across 11 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 99.93% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001012975-25-000444

Period
2025-06-30
Reported value
$299M
Holdings
11
Top 10 weight
99.93%
New
3
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VIRnew+12,916,663$65.1M
LYELnew+1,820,634$16.1M
CEROnew+22,389$216K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CERO THERAPEUTICS HLDGS INCexited-22,102-$16.1K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001012975-25-000444, largest first. % of portfolio is the value over $299,110,134, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,834,653 shares; 2024Q4: 4,540,132 shares; 2025Q1: 4,540,132 shares; 2025Q2: 4,540,132 shares 4,540,132$77.2M25.82%0Timeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 12,916,663 shares 12,916,663$65.1M21.76%newTimeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,120,053 shares; 2025Q2: 4,120,053 shares 4,120,053$50.6M16.91%0Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,728,738 shares; 2024Q4: 3,728,738 shares; 2025Q1: 3,728,738 shares; 2025Q2: 3,728,738 shares 3,728,738$42.4M14.19%0Timeline
VERVE THERAPEUTICS INCVERVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,008,809 shares; 2024Q4: 2,008,809 shares; 2025Q1: 2,008,809 shares; 2025Q2: 2,008,809 shares 2,008,809$22.6M7.54%0
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,820,634 shares 1,820,634$16.1M5.39%newTimeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 11,055,554 shares; 2024Q4: 11,055,554 shares; 2025Q1: 11,055,554 shares; 2025Q2: 11,055,554 shares 11,055,554$14.1M4.71%0Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,055,916 shares; 2024Q4: 8,055,916 shares; 2025Q1: 8,055,916 shares; 2025Q2: 8,055,916 shares 8,055,916$9.91M3.31%0Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 320,482 shares; 2024Q4: 320,482 shares; 2025Q1: 320,482 shares; 2025Q2: 320,482 shares 320,482$478K0.16%0Timeline
UNITY BIOTECHNOLOGY INC COM…UNITY BIOTECHNOLOGY INC COM NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,004,817 shares; 2024Q4: 1,004,817 shares; 2025Q1: 1,004,817 shares; 2025Q2: 1,004,817 shares 1,004,817$386K0.13%0
CEROCERO THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 22,389 shares 22,389$216K0.07%newTimeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CERO THERAPEUTICS HLDGS INCCERO THERAPEUTICS HLDGS INC22,102$16.1Kshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-25-000444 base2025-08-14acceptance time not in the bulk data set